An interventional study of CEST sequence on a 7-Tesla MRI in Epilepsy (Treatment Refractory), sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild — 7 open to participants now, 7 under way, none of them phase 3. Epilepsy · Fondation Ophtalmologique Adolphe de Rothschild.
Among the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, this one is the only one that started in 2027, is one of 3 with no phase, and was the 10th registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →7 of the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild are open now, in 1 country. Recruiting first, the newest first:
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18+
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18–65 · Healthy volunteers
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18+
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 6–18
By country, each count listing its studies:
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2027.
This study's planned enrollment of 20 is below the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 76 across the 3 interventional studies, 50 across the 7 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.
3 of the studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07075380Fondation Ophtalmologique Adolphe de RothschildNational Survey on Physical and Sports Activity of Adults With Epilepsy | 2027-05 |
| NCT04451278Fondation Ophtalmologique Adolphe de RothschildRESting-state Functional MRI for Prediction of Post-surgical Prognosis In Pediatric Drug-Resistant Epilepsy | 2027-10 |
| NCT07026591Fondation Ophtalmologique Adolphe de RothschildEpilepsy and Driving | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Epilepsy is a common neurological disorder with an incidence of 1%. Although many anti-seizure medications are available, about 30% of patients are resistant to drug treatments. Epilepsy surgery is an effective treatment for some of these patients. It involves removing the brain region responsible for generating seizures, called the epileptogenic zone (EZ).
A pre-surgical evaluation is performed to locate and delineate the region where seizures originate (the seizure onset zone [SOZ]) and to confirm that this zone is unique and accessible for surgery-that is, that the potential benefits outweigh the risks of functional deficits resulting from its removal. The lesion itself is identified and characterized through post-operative histological examination and, in some cases, based on MRI criteria.
During pre-surgical evaluation, in cases where no lesion is visible on MRI or when surface EEG suggests that a large or multiple epileptic networks may be involved, stereo-electroencephalography (SEEG) is the method of choice to delineate the area for resection. However, SEEG has limitations: it is invasive and records from a restricted brain volume.
Despite advances in neuroimaging techniques, the localization of the epileptogenic zone and mapping of functional brain alterations still need improvement beyond what morphological MRI anomalies can reveal.
Because epileptic tissue is characterized by increased neuronal excitability and metabolic abnormalities, techniques that allow precise evaluation of these changes could deepen our understanding of the disease and provide new tools for epilepsy surgery. An alternative MRI approach based on metabolite quantification using chemical exchange saturation transfer (CEST) has been suggested to aid in localizing the epileptogenic zone in preliminary studies. However, limited availability of ultra-high-field MRI, low localization precision of the epileptogenic zone, and lack of systematic validation in patients have delayed its clinical use.
This study aims to explore a cohort of patients with temporal lobe epilepsy who are candidates for surgery using CEST MRI. We will quantify glutamate and glucose concentrations using glu-CEST and gluco-CEST, respectively, and correlate the results with the localization of the epileptogenic zone determined by pre-surgical evaluation, and where applicable, SEEG and post-operative outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: CEST sequence on a 7-Tesla MRI
CEST sequence on a 7-Tesla MRI
Glucose concentration measured by CEST in the the seizure onset zone (SOZ)
Time frame: Day 0
Glucose concentration measured by CEST in the irritative zone (IZ)
Time frame: Day 0
Glucose concentration measured by CEST in the propagation zone
Time frame: Day 0
Glutamate concentration measured by CEST in the seizure onset zone (SOZ)
Time frame: Day 0
Glutamate concentration measured by CEST in the irritative zone (IZ)
Time frame: Day 0
Glutamate concentration measured by CEST in the propagation zone
Time frame: Day 0
No study locations are listed for this record.
Start is estimated for Jan 2027; primary completion for Jan 2030, 36 months later.
Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 36 months is below that.
Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Mar 2026 → Jan 2027, primary completion Mar 2029 → Jan 2030 and completion Mar 2029 → Jan 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondation Ophtalmologique Adolphe de Rothschild →